David Shum,
Assay Development Specialist,
Memorial Sloan-Kettering Cancer Center
David Shum has over seven years of extensive drug discovery experience in assay development and screening. He joined the HTS Core in 2004 and has been at the forefront of developing high-content and biochemical assays for screening across therapeutic target areas in oncology, antivirals such as HIV and Dengue. To date, he has successfully performed over 20 screens for both chemical and RNAi libraries leading to the identification of several hits; one of which a CDC7 kinase inhibitor being currently developed for treating refractory cancers. David received his M.Sc. in Biology from New York University in 2002 and has been at Memorial Sloan-Kettering Cancer Center since 2002.
|
|
|
Add to Calendar ▼2011-04-26 09:30:002011-04-26 10:30:00Europe/LondonLentivirus Enabled shRNA Drug Modifier Screens: Panoramic View of the Human Genome One Hairpin at a TimeRNAi and miRNA World Congress in BostonBostonSELECTBIOenquiries@selectbiosciences.com
